Emergent BioSolutions announced that it was awarded a contract modification executing an option period by the Biomedical Advanced Research and Development Authority, BARDA, part of the Administration for Strategic Preparedness and Response, ASPR, within the U.S. Department of Health and Human Services, HHS, valued at $41.9 million, for drug substance engineering and scale-up process validation, long term stability, and commercial readiness in support of its ongoing scale-up program for Ebanga, a licensed treatment for Ebola virus disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
- Largest borrow rate increases among liquid names
- Emergent BioSolutions Secures $250M Loan and Adjusts Equity
- Emergent BioSolutions closes credit facility agreement with Oak Hill
- Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile